
News|Articles|November 1, 2005
Safety Labeling updates and new warnings
The manufacturer of ato-moxetine (Strattera, Lilly) was directed by FDA to revise the prescribing information for the drug to include a black box warning and additional statements that alert healthcare providers of an increased risk of suicidal thinking in children and adolescents being treated with this medication.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
ALK Testing Strategies and Navigating First-Line Treatment Options in Advanced NSCLC
2
How PBMs are tackling behavioral health
3
Most commercial plans cover SC and IV oncology therapies at parity
4
ALK-Positive NSCLC: Epidemiology, Prognosis, and the Critical Role of Biomarker Testing
5































